Scientific Reference

CJC-1295 (without DAC)

Evidence profile: Controlled human evidence

CJC-1295 (without DAC), also known as Modified GRF 1-29 (Mod GRF 1-29), is a short-acting synthetic analog of growth hormone releasing hormone (GHRH). It is designed to stimulate endogenous growth hormone (GH) release in a pulsatile, physiologically consistent manner. Unlike the DAC-modified version, this variant has a very short half-life, allowing precise control over GH pulses and reducing the risk of receptor desensitization. It is primarily used in research focused on recovery, anti-aging, body composition, and endocrine function optimization.

Mechanism of Action

CJC-1295 without DAC binds to GHRH receptors on pituitary somatotroph cells, stimulating cyclic AMP (cAMP) production and triggering pulsatile release of growth hormone. This mimics natural GH secretion patterns, leading to downstream increases in IGF-1 while preserving normal endocrine feedback mechanisms.

Molecular Information

Type: GHRH analog (Modified GRF 1-29)
Length: 30 amino acids
Molecular weight: 3647.2 g/mol
Molecular formula: C165H269N47O46

Published Research

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL et al. · The Journal of clinical endocrinology and metabolism · 2006 · Clinical
PMID 16352683 — View on PubMed
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M et al. · The Journal of clinical endocrinology and metabolism · 2006 · Clinical
PMID 17018654 — View on PubMed